Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17276351 | 0.83 | PDK2 (0.44) | HDAC4CYP11B2CYP11B1PDK2HDAC3 | |
| SCHEMBL17275591 | 0.81 | HDAC4 (0.40) | HDAC4CYP11B2CYP11B1HDAC3HDAC1 | |
| SCHEMBL6285519 | 0.79 | HDAC4 (0.44) | HDAC4CYP11B2CYP11B1PDK2HDAC3 | |
| SCHEMBL17276114 | 0.78 | PDK2 (0.39) | HDAC4CYP11B2CYP11B1PDK2 | |
| SCHEMBL17276110 | 0.76 | HDAC4 (0.43) | HDAC4CYP11B2CYP11B1PDK2HDAC3 | |
| SCHEMBL17276193 | 0.74 | PDK2 (0.45) | HDAC4PDK2HDAC3HDAC1HDAC2 | |
| SCHEMBL17276348 | 0.71 | PDK2 (0.52) | HDAC4PDK2CYP3A4 | |
| SCHEMBL17276288 | 0.66 | PDK2 (0.41) | HDAC4PDK2 | |
| SCHEMBL23003719 | 0.63 | KDM1A (0.44) | CYP11B2PDK2CYP17A1CYP3A4 | |
| SCHEMBL30491077 | 0.63 | HDAC4 (0.41) | HDAC4PDK2HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3145915-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-10000454-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170081287-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-03-23 | — | — | US | disclosed |
| WO-2015176267-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000454-B2 | Antidiabetic tricyclic compounds | GPR119, GPR65, GPR52 | HDAC4 549/4885CYP11B2 295/4885CYP11B1 285/4885 |
| US-20170081287-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR52 | HDAC4 549/4885CYP11B2 295/4885CYP11B1 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.